GSK has signed an eight-year emissions reduction purchase agreement for regenerative agriculture carbon credits from Indian developer Varaha, in a deal structured by nature-risk firm Earthly and announced this week. The agreement will finance the expansion of regenerative practices across 50,000 hectares of smallholder farmland in the northern states of Punjab and Haryana, with delivery of roughly 100,000 tonnes of removal credits per year between 2028 and 2033. For corporate buyers watching the agricultural carbon segment, the transaction is a useful benchmark: a large pharma buyer committing long-term capital to soil and practice-change credits, with integrity filters attached.
The Deal Mechanics
The agreement is an ERPA, a long-term contract in which GSK commits to purchasing credits over a defined period while Earthly holds the commercial terms, verification requirements and reporting obligations. Credits are structured for delivery through 2034, with quarterly reporting built in across four dimensions: carbon, water, farmer income and community engagement.
The underlying project transitions smallholder farmers away from residue burning, intensive tillage and flood-irrigated rice transplanting toward direct seeded rice, reduced tillage and the incorporation of crop residues into the soil. Farmers receive subsidised access to machinery plus a share of credit revenue, which is what makes the practice change economically rational at household level.
On integrity, the project is certified under Verra’s Verified Carbon Standard using methodology VM0042 for improved agricultural land management, and is listed on the Verra registry under ID 3346. As part of this agreement the project is upgrading to VM0042 version 2.2, which is already approved under the ICVCM’s Core Carbon Principles, so future issuances should qualify for the CCP label. Quantification relies on remote sensing and machine learning-based monitoring, independently verified. Earthly added a second screen through its Keystone 3.0 assessment, which the firm says fewer than 9% of nature projects pass.
Early Results From the First Monitoring Period
This is not a paper project selling forward on promise alone. Across 42,000 hectares in its first monitoring period, the project reports avoiding 4,574 tonnes of fine particulate matter (PM2.5) that would otherwise have been released through burning, and saving approximately 59.5 billion litres of water. Participating households saw average income rise by 12 to 16%, driven by higher yields, lower fertiliser spending and the farmers’ share of carbon revenue.
The air quality angle is not decorative. India burns roughly 100 million tonnes of crop residue a year, and seasonal burning in Punjab and Haryana is a significant contributor to the PM2.5 pollution that blankets the Indo-Gangetic Plain. Air pollution is linked to approximately 2 million premature deaths annually across South Asia. For a healthcare buyer, those co-benefits are the point: GSK has published, with Pollination, an open-source toolkit for embedding health considerations into nature-based project design, and this deal applies it.
Varaha, for its part, describes itself as Asia’s largest carbon removal developer, working with more than 200,000 farming families and delivering credits across four removal pathways: regenerative agriculture, agroforestry, biochar and enhanced rock weathering. Chief executive Madhur Jain framed the gap plainly: the agreement covers 50,000 hectares, while the burning happens across millions.
Why GSK Is Buying Early
The purchase covers approximately 7% of GSK’s forecasted residual emissions under its current reduction glidepaths. The company aims to cut its carbon emissions 80% by 2030 from a 2020 baseline, with the remainder addressed through high-quality nature protection and restoration investments.
Two timing details matter for market watchers. First, GSK plans to retire its first credits in 2030, five years earlier than the proposed minimum mandatory requirement under Version 2 of the Science Based Targets initiative’s Net Zero Standard. Second, the delivery window of 2028 to 2033 means GSK is paying now for supply that mostly does not exist yet, a classic forward-financing structure that de-risks the developer’s expansion in exchange for secured volume.
What This Signals for Buyers and Developers
For buyers, the deal reinforces three patterns that have been building all year. Long-duration ERPAs are becoming the default structure for serious agricultural carbon procurement, replacing spot purchases. Integrity layering is now standard: registry certification, a CCP-approved methodology upgrade, and an independent due diligence screen all stacked in one transaction. And co-benefits with a quantified line, whether PM2.5 avoided, water saved or farmer income gained, are moving from marketing annex to contractual reporting obligation.
For developers, the signal is that corporate demand for soil and practice-change credits exists at scale, but it is conditional. Varaha reached this deal with monitored results from a first period, a machine learning-based MRV stack and a methodology upgrade path already in motion. Projects without field-level data will find the due diligence bar hard to clear.
For investors, agricultural carbon in India continues to consolidate around a small number of platforms capable of operating at six-figure-hectare ambition with verifiable data. The constraint is no longer buyer interest. It is the supply of projects that can survive this level of scrutiny.
What to Watch
Three markers will show whether this deal template scales. First, the VM0042 v2.2 upgrade and the first CCP-labelled issuances from the project, which will test whether methodology migration delays credit delivery. Second, the quarterly reporting cadence: if GSK and Earthly publish outcome data across carbon, water and farmer income, it will set a transparency precedent other buyers will be measured against. Third, whether other pharma and healthcare buyers follow GSK into health-linked nature credits, turning a one-off structure into a segment.
